Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Using credit card points for vacation packages can lead to significant savings. Discover how to make the most of your rewards for a dream trip.
17,930 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Strategy reported a $12.54 billion Q1 loss driven by unrealized BTC declines, even as its software business expanded ...
Estridge breaks ground on Millbrook, a 345-acre mixed-use project in West Lafayette, set to add 1,000+ homes near Pur...
Star Group's Q2 2026 results shed light on the company's path to profitability and growth. This article breaks down t...
ETH failed to clear $2,400, hinting at a pullback toward the $2,000 zone. XRP lingers inside a pennant below $1.40, w...
The POWI 2026 earnings transcript sheds light on how the company performed in Q1 and what the path ahead could look l...
Frontier is expanding capacity in key markets after Spirit exits, betting on demand and scale. The move highlights a ...
When a trusted investment firm unloads a large stake, markets take notice. This article breaks down a real-world exit...
Chip stocks pause after a blistering run, with Intel crashing 10%, slides as investors take profits and reassess AI m...
Fuel shortages and higher prices threaten summer trips as airlines trim routes. Investors are reassessing bets on tra...
Lucid stock sits near $7, tempting bargain hunters. This article breaks down the real risks, the potential catalysts,...
A Two Harbors shareholder files a federal lawsuit to block the CCM merger vote, alleging deceptive proxy disclosures ...